CA2434685A1 - Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri - Google Patents
Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri Download PDFInfo
- Publication number
- CA2434685A1 CA2434685A1 CA002434685A CA2434685A CA2434685A1 CA 2434685 A1 CA2434685 A1 CA 2434685A1 CA 002434685 A CA002434685 A CA 002434685A CA 2434685 A CA2434685 A CA 2434685A CA 2434685 A1 CA2434685 A1 CA 2434685A1
- Authority
- CA
- Canada
- Prior art keywords
- mixture
- residue
- added
- nmr
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Saccharide Compounds (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002434685A CA2434685A1 (fr) | 2003-07-04 | 2003-07-04 | Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri |
CA002434668A CA2434668A1 (fr) | 2003-07-04 | 2003-07-07 | Nouvelle approche pour concevoir des glycopeptides a base de o-specifique polysaccharide de shigella flexneri serotype 2a |
DK10011475.0T DK2369345T3 (en) | 2003-07-04 | 2004-07-02 | Glycoconjugates and their use as potential vaccines against infection with Shigella flexneri |
US10/563,221 US8124380B2 (en) | 2003-07-04 | 2004-07-02 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri |
AT04744281T ATE514087T1 (de) | 2003-07-04 | 2004-07-02 | Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri |
DK04744281.9T DK1642132T3 (da) | 2003-07-04 | 2004-07-02 | Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri |
PCT/IB2004/002657 WO2005003775A2 (fr) | 2003-07-04 | 2004-07-02 | Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri |
EP10011475.0A EP2369345B1 (fr) | 2003-07-04 | 2004-07-02 | Glycoconjugués et leur utilisation comme vaccins potentiels contre une infection provoquée par shigella flexneri |
CA2470262A CA2470262C (fr) | 2003-07-04 | 2004-07-02 | Glyconconjugues et utilisation conenxe comme vaccins possibles contre l'infection par shigella flexneri |
CA2531023A CA2531023C (fr) | 2003-07-04 | 2004-07-02 | Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri |
EP04744281A EP1642132B1 (fr) | 2003-07-04 | 2004-07-02 | Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri |
US13/325,511 US9446109B2 (en) | 2003-07-04 | 2011-12-14 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002434685A CA2434685A1 (fr) | 2003-07-04 | 2003-07-04 | Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2434685A1 true CA2434685A1 (fr) | 2005-01-04 |
Family
ID=33569507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002434685A Abandoned CA2434685A1 (fr) | 2003-07-04 | 2003-07-04 | Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2434685A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114854645A (zh) * | 2022-06-10 | 2022-08-05 | 陕西师范大学 | 一种适合沙雷氏菌l-鼠李糖诱导表达系统的应用培养基和培养方法 |
-
2003
- 2003-07-04 CA CA002434685A patent/CA2434685A1/fr not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114854645A (zh) * | 2022-06-10 | 2022-08-05 | 陕西师范大学 | 一种适合沙雷氏菌l-鼠李糖诱导表达系统的应用培养基和培养方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9446109B2 (en) | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | |
Pozsgay | Synthesis of glycoconjugate vaccines against Shigella dysenteriae type 1 | |
Boltje et al. | Chemical synthesis and immunological evaluation of the inner core oligosaccharide of Francisella tularensis | |
US11191822B2 (en) | Pneumococcal polysaccharide-protein conjugate composition | |
Zhao et al. | Conjugation of synthetic trisaccharide of Staphylococcus aureus type 8 capsular polysaccharide elicits antibodies recognizing intact bacterium | |
Laverde et al. | Synthetic oligomers mimicking capsular polysaccharide diheteroglycan are potential vaccine candidates against encapsulated Enterococcal infections | |
Wang et al. | Chemical synthesis and immunological evaluation of fragments of the multiantennary group-specific polysaccharide of group B Streptococcus | |
US10087242B2 (en) | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | |
US10500262B2 (en) | Synthetic antigen constructs against Campylobacter jejuni | |
Qin et al. | Recent chemical synthesis and immunological evaluation of glycans related to bacterial lipopolysaccharides | |
Jamshidi et al. | Synthesis and immunogenicity of a methyl rhamnan pentasaccharide conjugate from Pseudomonas aeruginosa A-Band polysaccharide | |
US20240024489A1 (en) | Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof | |
CA2434685A1 (fr) | Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri | |
Basu et al. | Recent chemical syntheses of bacteria related oligosaccharides using modern expeditious approaches | |
WO1999003871A1 (fr) | Vaccin conjugue hexadecasaccharide-proteine contre shigella dysenteriae de type 1 | |
CA2531023C (fr) | Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri | |
US20150290331A1 (en) | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri | |
Jiao | Syntheses of carbohydrate antigens expressed by gastric-intestinal bacteria and conjugates thereof | |
WO2023168520A1 (fr) | Prévention/traitement d'une infection par pseudomonas aeruginosa | |
Jiao | An anti-Clostridium difficile vaccine: chemical synthesis of the pentasaccharide repeating unit of polysaccharide PS-I | |
Schumann | Synthesis and Immunological Evaluation of Oligosaccharide-Antigens as Vaccine Candidates for Streptococcus pneumoniae Serotypes 1 and 8 | |
KR20200106034A (ko) | 클렙시엘라 뉴모니아에 대한 백신 | |
Guo | I. Synthetic bacterial lipopolysaccharide core structures as vaccine candidates against Clamydia trachomatis and Yersinia pestis: II. Synthesis of a fungal galectin epitope trisaccharide and the HNK-1 epitope trisaccharide | |
Cheng | Development of alkyl imidate glycosylation method and application to allyl Lewis A synthesis | |
CA2511084A1 (fr) | Conjugues carbohydrate-phosphorylcholine et utilisations vaccinales, therapeutiques et diagnostiques connexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |